News >

Brentuximab Vedotin Receives Breakthrough Therapy Designation for Frontline Hodgkin Lymphoma

Jason Harris
Published: Monday, Oct 02, 2017

Clay Siegall, PhD

Clay Siegall, PhD
The FDA has awarded brentuximab vedotin (Adcetris) a breakthrough therapy designation for the first-line treatment of patients with classical Hodgkin lymphoma, Seattle Genetics, the company developing the antibody-drug conjugate, announced today.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication